|
Profit before tax (PBT) stood at Rs 102.3 crore in Q2 September 2019 compared with Rs 88.1 crore in Q2 last year, a growth of 16.1%.
Operating revenue increased by 15.1% in Q2 September 2019 to Rs 365.6 crore as against Rs 317.5 crore in the previous year same quarter. Underlying patient volume growth is 12.1% during the quarter.
Normalised EBITDA (after adjustment for stock based compensation, CSR cost & impact of Ind AS 116) for Q2 September 2019 grew 15.7% to Rs 104.7 crore from Rs 90.5 crore in the same quarter last year. Normalised EBITDA Margin ex Ind AS 116 at 28.6% for Q2 September 2019.
The company declared an interim dividend of Rs 6 per share.
Shares of Dr. Lal PathLabs declined 2.91% to Rs 1451.80 on Friday, 8 November 2019.
Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India.
|